|
Bayer's Commitment
Bayer, in partnership with the AVMA, supports the profession with programs vital to the continued growth of veterinary medicine. Symposia, continuing education, practice building campaigns, and research that develops unique products including K9 Advantix™, triple protection for dogs against biting fleas, ticks and mosquitoes; Advantage®, the fastest flea control; Baytril® (enrofloxacin), the first veterinary fluoroquinolone; Drontal® dewormers; Legend® (hyaluronate sodium), the only approved IV joint therapy; and Marquis® (ponazuril), the first approved treatment for EPM, demonstrate Bayer's ongoing commitment. For the future, Bayer pledges to focus on optimum animal health and welfare within a strengthened veterinary economy.
About Bayer Animal Health
Bayer is a leader in the animal health industry, with products that represent breakthrough discoveries that change the practice of veterinary medicine. These scientific discoveries include the first chloronicotinyl insecticide for flea control, the first fluoroquinolone specifically for veterinary use, the first cestocide noted by the World Health Organization, the first hyaluronic acid for IV joint therapy, the first FDA approved treatment for Equine Protozoal Myeloencephalitis, and the first systemic for bovine parasite control. Bayer is also recognized for their professional colleagues who provide the highest quality technical information and customer service.
Summary
Bayer's continued commitment to the veterinary profession extends beyond quality products to substantial financial commitments to the AVMA and other associations, resources to help veterinarians communicate the pet health message to their clients, and support of economic initiatives to advance animal health and strengthen the veterinary economy.
ACKNOWLEDGEMENT
The AVMA gratefully acknowledges Bayer Animal Health, whose generous contributions
support:
AVMA Annual Convention
Compendium of Veterinary Products
AVMA Veterinary Career Center |
